<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806558</url>
  </required_header>
  <id_info>
    <org_study_id>12-004900</org_study_id>
    <nct_id>NCT01806558</nct_id>
  </id_info>
  <brief_title>Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions</brief_title>
  <acronym>MBI/US</acronym>
  <official_title>Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A combined molecular breast imaging / ultrasound system will enable coregistration of a
      functional abnormality seen on Molecular Breast Imaging (MBI) with the corresponding
      anatomical abnormality seen on ultrasound.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2012</start_date>
  <completion_date type="Actual">June 1, 2017</completion_date>
  <primary_completion_date type="Actual">May 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the potential benefits of co-registered MBI and ultrasonic information relative to independent acquisition of each modality.</measure>
    <time_frame>1 year</time_frame>
    <description>Presence / absence of correlation between lesion seen on ultrasound and lesion seen on MBI.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Women with lesion on MBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with lesion on MBI</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Molecular Breast Imaging</intervention_name>
    <description>Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.</description>
    <arm_group_label>Women with lesion on MBI</arm_group_label>
    <other_name>MBI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The pilot study will comprise 12 women age 40 and older who have at least one of the
             following inclusion criteria:

               1. Have a finding of a mass lesion on mammography or breast MRI (BIRADS 0, 4 or 5)
                  that is &gt;0.5 cm and &lt; 2 cm in size and has had or will have additional workup
                  with focused ultrasound.

               2. Have a finding of a mass lesion on ultrasound (BIRADS 0, 4 or 5) that is &gt; 0.5 cm
                  and &lt; 2 cm in size.

               3. Have a positive finding on MBI that is &lt; 2 cm in size and requires additional
                  diagnostic workup with focused ultrasound.

        Exclusion Criteria:

          1. Are unable to understand and sign the consent form

          2. Are pregnant or lactating

          3. Are physically unable to sit upright and still for 40 minutes

          4. Have undergone bilateral mastectomy

          5. Are not scheduled to undergo conventional ultrasound
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael K O'Connor, PhD, R-D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.youtube.com/watch?v=DOQBLe8MdH0</url>
    <description>Mayo Clinic You Tube Channel</description>
  </link>
  <results_reference>
    <citation>Rhodes DJ, Hruska CB, Phillips SW, Whaley DH, O'Connor MK. Dedicated dual-head gamma imaging for breast cancer screening in women with mammographically dense breasts. Radiology. 2011 Jan;258(1):106-18. doi: 10.1148/radiol.10100625. Epub 2010 Nov 2.</citation>
    <PMID>21045179</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2013</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michael O'Connor</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>molecular breast imaging</keyword>
  <keyword>breast</keyword>
  <keyword>breast lesion</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

